Compare Norfolk Southern Corporation (NSC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Norfolk Southern Corporation trades at $333.81 (market cap $75.01B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Norfolk Southern Corporation and Regeneron Pharmaceuticals Inc are close in size by market cap, and Norfolk Southern Corporation pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| NSC | REGN | |
|---|---|---|
Market Cap | $75.01B | $83.19B |
Sector | Technology | Health |
52-Week High | $350.66 | $812.27 |
52-Week Low | $272.35 | $555.51 |
Enterprise Value | $90.55B | $77.90B |
Dividend Yield | 1.62% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $334.36, down 2.37% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 21.02% net income margin and consistent earnings beats, with Q2 2026 EPS of $3.52 exceeding expectations. Recent news highlights a potential merger with Union Pacific, adding to positive sentiment amid record revenue growth.
Outlook remains favorable due to operational strength and merger prospects, but risks include high valuation (P/E 28.49) and industry headwinds like fuel costs. Analysts are mixed, with a consensus price target of $369.67, suggesting moderate upside potential from current levels.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
